| pioglitazone / Generic mfg. |
NCT00227110: Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) |
|
|
| Completed | 4 | 55 | US | Pioglitazone, Actos (Takeda Pharmaceuticals)., Placebo | The University of Texas Health Science Center at San Antonio, National Institutes of Health (NIH), Takeda Pharmaceuticals North America, Inc. | Nonalcoholic Steatohepatitis | 11/05 | 01/06 | | |
| Completed | 4 | 40 | US | Pioglitazone, Actos, Placebo Oral Tablet | University of Michigan | Chronic Hepatitis C | 12/07 | | | |
NCT00545233: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance. |
|
|
| Completed | 4 | 155 | US | peginterferon alfa-2a [Pegasys], Pegasys, ribavirin [Copegus], Copegus, Pioglitazone, Actos | Hoffmann-La Roche | Hepatitis C, Chronic | 12/10 | 12/10 | | |
NCT00926614: Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba |
|
|
| Completed | 4 | 20 | US | pioglitazone (Actos), Actos, atorvastatin (Lipitor), Lipitor | Brooke Army Medical Center | Hepatitis c | 06/11 | 12/11 | | |
NCT00742326: Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections |
|
|
| Terminated | 4 | 13 | US | Pioglitazone, Avandia, Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | HIV, Hepatitis C, Liver Disease, Fatty Liver, Steatosis | 01/13 | 01/13 | | |
| Completed | 4 | 176 | US | Pioglitazone study drug, Actos (brand name), manufactured by Takeda Pharmaceuticals., Placebo, Pioglitazone Open Label | University of Florida, The University of Texas at San Antonio | Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus | 12/14 | 12/14 | | |
VA NASH, NCT01002547: Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment |
|
|
| Completed | 4 | 105 | US | pioglitazone-placebo, pioglitazone, Actos, Vitamin E, Vitamin E-placebo | VA Office of Research and Development | Nonalcoholic Steatohepatitis | 09/16 | 12/16 | | |
NCT02365233: Fatty Liver Study in Patients With Type II Diabetes |
|
|
| Terminated | 4 | 5 | US | DPP4 inhibitor, sitagliptin100 mg daily, saxagliptin 5 mg daily, Pioglitazone, Pioglitazone 15 mg daily, Lantus insulin, Lantus insulin (0.35U/kg of body weight once daily) | The University of Texas Medical Branch, Galveston | Type II Diabetes, Nonalcoholic Fatty Liver | 12/16 | 12/16 | | |
